Sejong-si, South Korea

Myung Ho Sohn

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2022

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Myung Ho Sohn: Innovating Antibody Fc Variants in Sejong-si, KR

Introduction

Myung Ho Sohn is a distinguished inventor based in Sejong-si, South Korea. He is recognized for his innovative contributions to the field of biotechnology, particularly in the development of antibody Fc variants aimed at improving therapeutic efficacy. With 1 patent to his name, his work has substantial implications for cancer treatment and diagnostic applications.

Latest Patents

The patent attributed to Myung Ho Sohn, titled "Antibody Fc variants for increased blood half-life," presents a polypeptide that includes an Fc variant produced by substituting part of the amino acid sequence of the Fc domain of a human antibody. This invention not only encompasses the polypeptide but also includes an antibody featuring this polypeptide. The Fc variant has broad applicability across various antibodies and Fc-fusion constructs. Notably, it is engineered to enhance the in vivo half-life, particularly beneficial in therapeutic contexts such as cancer treatment. This antibody or Fc fusion construct can effectively target cells that express specific antigens, including cancer cells, or may be utilized to modulate cytokine activities.

Career Highlights

Myung Ho Sohn has made significant strides in his career through his affiliations with prominent institutions, notably Kookmin University and the Osong Medical Innovation Foundation. His persistent dedication to research and innovation has been a key driver of his success as an inventor.

Collaborations

Throughout his career, Myung Ho Sohn has had the opportunity to collaborate with talented professionals, including Sang Taek Jung and Sanghwan Ko. These partnerships have undoubtedly contributed to his research advancements and the development of his impactful patent.

Conclusion

In conclusion, Myung Ho Sohn's work in developing antibody Fc variants showcases his commitment to innovation in the biotechnology sector. With a strong patent portfolio and collaboration with esteemed institutions and colleagues, he continues to pave the way for advancements that hold promise in therapeutic applications for cancer and beyond. His contributions are a testament to the transformative power of scientific innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…